LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 540 participants.

Also called NCT07288398

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 540 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07288398
  • EU CT 2025-522475-28-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Austria, Brazil, Bulgaria, Czechia, France, Germany, Hungary, Italy, Poland, South Korea, Spain, Taiwan, United Kingdom (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT07288398. Randomized; quadruple masking; primary purpose treatment. Start 2026-03-03 (actual); primary completion 2028-06-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
Acronym
LEVEL-2
Condition
Pulmonary Hypertension Associated With HFpEF
Intervention (Drug)
TNX-103
Intervention (Drug)
Placebo
Lead sponsor
Tenax Therapeutics, Inc. (class: industry)

Record details

Record id
cardio:ct-nct07288398
Content hash
eeb3e787137fc5f249518d394e31a932169d9519d1ad4b4c72ba22f8e8970d5b